(MCOV-B) Medicover (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0009778848
MCOV-B: Healthcare, Diagnostic, Services
Medicover AB (publ) is a leading healthcare and diagnostic services provider operating in Poland, India, Romania, Sweden, and other international markets. Established in 1995 and headquartered in Stockholm, Sweden, the company offers a comprehensive range of healthcare services, including outpatient and inpatient care, dental services, and non-medical related offerings such as sports memberships, benefit cards, optics, and wellness programs. Additionally, Medicover provides hospital care and preventive care services, ensuring a holistic approach to patient health.
The companys diagnostic services encompass a wide array of laboratory tests, spanning routine to advanced clinical pathology areas. These include allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry, immunochemistry, blood group diagnostics, transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. These services cater to corporate clients, individuals, and public payers, ensuring broad accessibility to diagnostic solutions.
From a technical perspective, Medicover AB (publ) is trading at 215.00 SEK with a 20-day average volume of 52,815 shares. The stocks short-term trend, indicated by the SMA20 (200.37), suggests recent upward momentum, while the SMA50 (202.79) and SMA200 (192.49) reflect longer-term growth potential. The ATR of 8.22 indicates moderate volatility, suggesting manageable risk for traders.
Fundamentally, the company has a market capitalization of 29,667.47M SEK, with a trailing P/E of 160.65 and a forward P/E of 64.94, indicating elevated valuations relative to earnings. The P/B ratio of 5.85 reflects a premium on book value, while the P/S ratio of 14.18 highlights strong revenue multiples. The return on equity (RoE) of 3.59% suggests modest profitability relative to shareholder equity.
3-Month Forecast:
Based on the SMA20 crossing above the SMA50 and SMA200, coupled with moderate ATR, Medicover AB (publ) is expected to maintain its upward trajectory in the short term. The stock may face resistance near 220 SEK, with potential pullbacks supported at the SMA20 level of 200.37. Fundamentally, the companys high valuation multiples suggest a focus on growth execution to justify current prices.
Additional Sources for MCOV-B Stock
MCOV-B Stock Overview
| Market Cap in USD | 3,322m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception |
MCOV-B Stock Ratings
| Growth Rating | 43.5 |
| Fundamental | 14.9 |
| Dividend Rating | 57.7 |
| Rel. Strength | 36.6 |
| Analysts | - |
| Fair Price Momentum | 236.72 SEK |
| Fair Price DCF | 41.89 SEK |
MCOV-B Dividends
| Dividend Yield 12m | 0.76% |
| Yield on Cost 5y | 1.79% |
| Annual Growth 5y | 14.42% |
| Payout Consistency | 98.0% |
MCOV-B Growth Ratios
| Growth Correlation 3m | -3.8% |
| Growth Correlation 12m | 37.5% |
| Growth Correlation 5y | 17.8% |
| CAGR 5y | 21.33% |
| CAGR/Max DD 5y | 0.31 |
| Sharpe Ratio 12m | -0.13 |
| Alpha | 33.37 |
| Beta | 0.499 |
| Volatility | 39.79% |
| Current Volume | 127k |
| Average Volume 20d | 61.5k |
As of May 01, 2025, the stock is trading at SEK 241.50 with a total of 127,005 shares traded.
Over the past week, the price has changed by +14.45%, over one month by +27.87%, over three months by +18.06% and over the past year by +38.98%.
Neither. Based on ValueRay Fundamental Analyses, Medicover (publ) is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.87 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MCOV-B as of May 2025 is 236.72. This means that MCOV-B is currently overvalued and has a potential downside of -1.98%.
Medicover (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, MCOV-B Medicover (publ) will be worth about 257.8 in May 2026. The stock is currently trading at 241.50. This means that the stock has a potential upside of +6.74%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 220.9 | -8.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 257.8 | 6.7% |